James Dean, MD, Senior Medical Director at Pharmacyclics, discusses outcomes of a pooled analysis of 4 clinical trials of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) as well as outcomes of an integrated analysis of the RESONATE-2 and iLLUMINATE clinical trials.
CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes, and blood. The disease is treatable, but relapse is very common.
As Dr. Dean explains in the video, the pooled analysis, presented at ASH 2020, combined data from 4 clinical trials to determine long-term survival, progression-free survival (PFS), and safety of CLL patients with the del(17p) or TP53 mutation treated with ibrutinib. Results from this pooled analysis demonstrated that over 75% of patients taking ibrutinib demonstrated PFS at extended follow-up. This suggests that ibrutinib is as efficacious a treatment for CLL patients with the del(17p) or TP53 mutation as it is for patients without these mutations.
In the second integrated analysis, the RESONATE-2 study involving CLL patients without a del(17p) and the iLLUMINATE study involving CLL patients with del(17p), del(11q), or mutations in IGHV, TP53, BIRC3, SF3B1, NOTCH1, or XPO1 genes were pooled and the data suggested ibrutinib to be an efficacious treatment for CLL patients regardless of gene mutations. Furthermore, according to Dr. Dean, the pooled data noted high safety levels for ibrutinib regardless of gene mutations as well.
For more information about CLL and other rare cancers, visit checkrare.com/diseases/cancers/